Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9423–9431 | Cite as

Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients

  • Ying Zhang
  • Wei Hua
  • Li-chun Niu
  • Shi-mei Li
  • Ying-mei Wang
  • Lei Shang
  • Cun Zhang
  • Wei-na Li
  • Rui Wang
  • Bi-liang Chen
  • Xiao-yan Xin
  • Ying-qi Zhang
  • Jian Wang
Original Article

Abstract

The purpose of this study was to determine the expression of growth differentiation factor 15 (GDF15) and explore its clinical significance in epithelial ovarian cancer (EOC) patients. The expression of GDF15 in EOC tissues and serum samples was evaluated using immunohistochemistry and enzyme-linked immunosorbent assay (ELISA), respectively. The association of GDF15 expression with clinicopathologic parameters was analyzed. Survival time was assessed using the Kaplan–Meier technique and Cox regression model. Both in EOC tissues and serum, high GDF15 levels were obviously related with advanced International Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis, ascites, and chemoresistance. Kaplan–Meier analysis indicated that EOC patients with high GDF15 expression showed poorer progression-free survival (PFS) and overall survival (OS). Multivariate analysis demonstrated that GDF15 expression was an independent predictor of PFS in EOC patients. Our study shows that elevated GDF15 expression was associated with poor prognosis in EOC patients. We suggest that GDF15 is a novel biomarker for the early detection of EOC, prediction of the response to chemotherapy, and screening for recurrence in EOC patients.

Keywords

Growth differentiation factor 15 Epithelial ovarian cancer Biomarker Chemotherapy Prognosis 

References

  1. 1.
    Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CACancer J Clin. 2014;64(1):9–29.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342(2):257–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Menczer J, Ben-Shem E, Golan A, et al. The significance of normal pretreatment levels of CA125 (<35 U/mL) in epithelial ovarian carcinoma. Rambam Maimonides Med J. 2015;6(1):e0005.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cohen JG, White M, Cruz A, et al. In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem. 2014;5(3):286–300.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nature reviews. Clin Oncol. 2010;7(6):335–9.Google Scholar
  8. 8.
    Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006;98(3):294–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Eling TE, Baek SJ, Shim M, et al. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol. 2006;39(6):649–55.PubMedGoogle Scholar
  11. 11.
    Breit SN, Johnen H, Cook AD, et al. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 2011;29(5):187–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003;9(7):2642–50.PubMedGoogle Scholar
  13. 13.
    Yang G, Tan Q, Xie Y, et al. Variations in NAG-1 expression of human gastric carcinoma and normal gastric tissues. Exp Ther Med. 2014;7(1):241–5.PubMedGoogle Scholar
  14. 14.
    Kaur S, Chakraborty S, Baine MJ, et al. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One. 2013;8(2):e55171.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mehta RS, Song M, Bezawada N, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014;106(4):dju016.Google Scholar
  16. 16.
    Marjono AB, Brown DA, Horton KE, et al. Macrophage inhibitory cytokine-1 in gestational tissues and maternal serum in normal and pre-eclamptic pregnancy. Placenta. 2003;24(1):100–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10(7):2386–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Kaku T, Watanabe S, Ohishi Y. [Pathology of ovarian cancer]. Nihon rinsho. Jap J Clin Med. 2012;70(l 4):512–516.Google Scholar
  20. 20.
    Simon R, Mirlacher M, Sauter G. Immunohistochemical analysis of tissue microarrays. Methods Mol Biol. 2010;664:113–26.CrossRefPubMedGoogle Scholar
  21. 21.
    Vaughan S, Coward JI, Bast Jr RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hogdall EV, Christensen L, Kjaer SK, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol. 2007;104(3):508–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Nossov V, Amneus M, Su F, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol. 2008;199(3):215–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Van Nagell Jr JR, Pavlik EJ. Ovarian cancer screening. Clin Obstet Gynecol. 2012;55(1):43–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res. 2011;4(9):1356–9.CrossRefGoogle Scholar
  26. 26.
    Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Gynecol Oncol. 2010;116(1):57–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang X, Baek SJ, Eling TE. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol. 2013;85(5):597–606.CrossRefPubMedGoogle Scholar
  28. 28.
    Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98(3):342–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Buckhaults P, Rago C, Croix BS, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 2001;61(19):6996–7001.PubMedGoogle Scholar
  30. 30.
    Park JY, Park KH, Bang S, et al. Expression of nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) inversely correlates with tumor progression in gastric adenomas and carcinomas. J Cancer Res Clin Oncol. 2008;134(9):1029–35.CrossRefPubMedGoogle Scholar
  31. 31.
    Blanco-Calvo M, Tarrio N, Reboredo M, et al. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer. Future Oncol. 2014;10(7):1187–202.CrossRefPubMedGoogle Scholar
  32. 32.
    Schiegnitz E, Kammerer PW, Koch FP, et al. GDF 15 as an anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma. Oral Oncol. 2012;48(7):608–14.CrossRefPubMedGoogle Scholar
  33. 33.
    Yang CZ, Ma J, Zhu DW, et al. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma. Ann Oncol. 2014;25(6):1215–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Wallin U, Glimelius B, Jirstrom K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer. 2011;104(10):1619–27.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Shnaper S, Desbaillets I, Brown DA, et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer. 2009;125(11):2624–30.CrossRefPubMedGoogle Scholar
  36. 36.
    Staff AC, Bock AJ, Becker C, et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol. 2010;118(3):237–43.CrossRefPubMedGoogle Scholar
  37. 37.
    Bock AJ, Stavnes HT, Kempf T, et al. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer. 2010;20(9):1448–55.PubMedGoogle Scholar
  38. 38.
    Meier JC, Haendler B, Seidel H, et al. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis. Cancer Med. 2015;4(2):253–67.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Ying Zhang
    • 1
    • 2
  • Wei Hua
    • 3
  • Li-chun Niu
    • 2
  • Shi-mei Li
    • 2
  • Ying-mei Wang
    • 3
  • Lei Shang
    • 4
  • Cun Zhang
    • 1
  • Wei-na Li
    • 1
  • Rui Wang
    • 4
  • Bi-liang Chen
    • 5
  • Xiao-yan Xin
    • 5
  • Ying-qi Zhang
    • 1
  • Jian Wang
    • 5
  1. 1.The State Key Laboratory of Cancer Biology, Biotechnology Center, School of PharmacyThe Fourth Military Medical UniversityXi’anChina
  2. 2.Department of Gynecology and ObstetricsThe People’s Liberation Army 323 HospitalXi’anChina
  3. 3.State Key Laboratory of Tumor Biology, Department of Pathology, Xijing HospitalThe Fourth Military Medical UniversityXi’anChina
  4. 4.Department of Health Service, School of Public HealthFourth Military Medical UniversityXi’anChina
  5. 5.Department of Gynecology and Obstetrics, Xijing HospitalFourth Military Medical UniversityXi’anChina

Personalised recommendations